# Additional file 1

**Table Additional file 1**: Efficacy (median PFS and median OS) and costs associated with each first-line treatments

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Treatments** | **Progression-free survival** | | | **Overall survival** | | | **Cost/week (€)***‡* | |
| **mPFS** | **Reference** | **mOS** | | **Reference** |  | |
| ALK+ | Alectinib | 34.8 | (30) | n.r | | Data on file | € 1.298 | |
| Crizotinib | 10.9 | (30) | 57.4 | | (30) | € 1.129 | |
| EGFR+ | Erlotinib | 9.7 | (31,32) | 31.8 | | (31,32) | € 275 | |
| Gefitinib | 9.7 | (31,32) | 31.8 | | (31,32) | € 286 | |
| Afatinib | 9.7 | Assumption\* | 31.8 | | (31,32) | € 441 | |
| Osimertinib | 17.7 | (31,32) | 38.6 | | (31,32) | € 1.309 | |
| Dacomitinib | 14.7 | (33) | 34.10 | | (33) | € 583 | |
| ROS | Crizotinib | 19.3 | (10) | 51.4 | | (10) | € 1.129 | |
| Entrectinib | 19.3 | Assumption | 51.4 | | Assumption | € 1.242 | |
| WT | Pembro monotherapy | 10.3 | (34,35) | 26.3 | | (34,35) | € 6.597 *¥* | |
| Cisplatin+pemetrexed | 4.9 | (36) | 10.7 | | (36) | Cisp*¥*: € 30 (4 cycles)  Pmtrx*¥* : € 2.009 | |
| Cisplatin+pemetrexed+  pembrolizumab | 9.0 | (36) | 22.0 | | (36) | Cisp*¥*: 30 € (4 cycles)  Pmtrx*¥* : 2.009 €  Pembro*¥*: 6.597 € | |
| Carboplatin+paclitaxel+  bevacizumab | 6.2 | (37) | 12.3 | | (37) | Carb+ pcltx*¥*: 573 € (4 cycles)  Beva*¥*: 3.218 € | |
| Carboplatin+paclitaxel+  bevacizumab+atezolizumab | 8.3 | (38) | 19.2 | | (38) | Carb+ pcltx*¥*: 573 € (4 cycles)  Beva*¥*: 3.218 €  Atezo*¥*: 4.152 € | |

*EGFR: epidermal growth factor receptor; ALK: anaplastic lymphoma kinase; ROS1: c-ros oncogene 1; WT: wild-type; Carb: carboplatin; pmtrx: pemetrexed; pcltx; paclitaxel; beva: bevacizumab; mPFS: median Progression free survival; mOS: median overall survival; n.r.: not reached.*

*\* assumed the same efficacy for afatinib as for erlotinib and gefitinib; ¥ costs are expressed as cost each 3 weeks; ‡ drug acquisition costs were obtained from (39)*